Immunotherapeutic Approaches in Triple-Negative Breast Cancer: State of the Art and Future Perspectives.
Journal
International journal of breast cancer
ISSN: 2090-3170
Titre abrégé: Int J Breast Cancer
Pays: Egypt
ID NLM: 101568103
Informations de publication
Date de publication:
2020
2020
Historique:
received:
15
05
2020
accepted:
16
06
2020
entrez:
18
11
2020
pubmed:
19
11
2020
medline:
19
11
2020
Statut:
epublish
Résumé
Triple-negative breast cancer (TNBC) is characterized by the absence of estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor 2 (HER2). It accounts for 15%-20% of all breast cancers and is associated with an aggressive evolution and poor outcomes with the majority of recurrences and deaths occurring in the first 5 years. Chemotherapy remains the mainstay of treatment in the absence of effective targets, but the good understanding of immune tumor microenvironment, the identification of immune-related targets, and the role of tumor-infiltrating lymphocytes (TILs) in TNBC has allowed to develop promising immunotherapeutic strategies for this unique subset of breast cancer. Recently, immunotherapy is being extensively explored in TNBC and clinical trials have shown promising results. In this article, we tried to explain the rationale and mechanisms of targeting the immune system in TNBC, to report the results from recent clinical trials that put immunotherapy as a new standard of care in TNBC in addition to ongoing trials and future directions in the next decade.
Identifiants
pubmed: 33204535
doi: 10.1155/2020/8209173
pmc: PMC7661147
doi:
Types de publication
Journal Article
Review
Langues
eng
Pagination
8209173Informations de copyright
Copyright © 2020 Karima Oualla et al.
Déclaration de conflit d'intérêts
The authors declare that they have no conflicts of interest.
Références
N Engl J Med. 2018 Nov 29;379(22):2108-2121
pubmed: 30345906
Proc Natl Acad Sci U S A. 2014 Oct 14;111(41):14710-5
pubmed: 25267626
PLoS One. 2014 Dec 15;9(12):e114900
pubmed: 25506917
Front Immunol. 2019 Aug 27;10:2022
pubmed: 31507611
Oncology. 2015;89(6):337-44
pubmed: 26413775
Nature. 2017 Aug 24;548(7668):471-475
pubmed: 28813415
Oncol Lett. 2018 Sep;16(3):2813-2822
pubmed: 30127867
Ann Oncol. 2019 Aug 1;30(8):1279-1288
pubmed: 31095287
JAMA Oncol. 2019 Aug 01;5(8):1132-1140
pubmed: 31194225
Oncoimmunology. 2013 Jul 1;2(7):e24720
pubmed: 24073365
JAMA Oncol. 2019 Jan 1;5(1):74-82
pubmed: 30242306
Breast Cancer Res. 2012 Mar 15;14(2):R48
pubmed: 22420471
J Immunother Cancer. 2019 Jan 16;7(1):12
pubmed: 30651126
Med Sci (Paris). 2019 Jun-Jul;35(6-7):527-534
pubmed: 31274082
Immunotherapy. 2018 Jul;10(9):769-778
pubmed: 29926750
Annu Rev Immunol. 2008;26:677-704
pubmed: 18173375
Lancet. 2020 Dec 5;396(10265):1817-1828
pubmed: 33278935
Breast Cancer Res Treat. 2014 Dec;148(3):467-76
pubmed: 25361613
Breast Cancer Res. 2015 Sep 04;17:124
pubmed: 26341640
Ther Adv Med Oncol. 2017 Jul;9(7):493-511
pubmed: 28717401
J Clin Oncol. 2016 Jul 20;34(21):2460-7
pubmed: 27138582
Nature. 2012 Oct 4;490(7418):61-70
pubmed: 23000897
PLoS One. 2016 Jun 16;11(6):e0157368
pubmed: 27310713
Clin Cancer Res. 2015 Apr 1;21(7):1688-98
pubmed: 25208879
J Natl Cancer Inst. 2016 Oct 5;109(1):
pubmed: 27707838
Ther Adv Med Oncol. 2013 May;5(3):169-81
pubmed: 23634195
Cancer Immunol Res. 2014 Apr;2(4):361-70
pubmed: 24764583
Clin Cancer Res. 2007 Aug 1;13(15 Pt 1):4429-34
pubmed: 17671126
Ann Oncol. 2022 May;33(5):534-543
pubmed: 35182721
Front Immunol. 2019 May 24;10:1149
pubmed: 31178870
Clin Cancer Res. 2016 Sep 1;22(17):4309-21
pubmed: 27390348
Cancer Res. 2017 Nov 15;77(22):6340-6352
pubmed: 28947417
Cancer Discov. 2018 Feb;8(2):216-233
pubmed: 29101163
N Engl J Med. 2020 Feb 27;382(9):810-821
pubmed: 32101663
Biochem Biophys Res Commun. 2018 Jul 7;502(1):160-165
pubmed: 29792857
Clin Adv Hematol Oncol. 2015 Jun;13(6):372-82
pubmed: 26352893
J Clin Invest. 2011 Jul;121(7):2750-67
pubmed: 21633166